Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) Short Interest Update

Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) was the target of a large decrease in short interest in July. As of July 31st, there was short interest totaling 37,127 shares, a decrease of 53.9% from the July 15th total of 80,592 shares. Based on an average daily trading volume, of 138,153 shares, the short-interest ratio is currently 0.3 days. Approximately 0.7% of the company’s shares are sold short.

Regentis Biomaterials Stock Performance

Regentis Biomaterials stock traded up $0.10 during mid-day trading on Friday, hitting $2.00. 55,057 shares of the company’s stock were exchanged, compared to its average volume of 104,447. The company’s 50 day simple moving average is $2.97 and its 200-day simple moving average is $3.16. Regentis Biomaterials has a fifty-two week low of $1.23 and a fifty-two week high of $15.50.

Institutional Investors Weigh In On Regentis Biomaterials

A hedge fund recently bought a new stake in Regentis Biomaterials stock. AIGH Capital Management LLC acquired a new stake in shares of Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned approximately 5.79% of Regentis Biomaterials at the end of the most recent reporting period.

About Regentis Biomaterials

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing tissue repair solutions which seek to restore the health. Regentis Biomaterials Ltd. is based in Herzliya, Israel.